Kati Vinnikainen Foto: Privat
However, while the infection rates in Bergen are lower than in many other cities, it is not the only reason the exchange students are looking forward to their semester here. Even though the classes are online, that does not make traveling less appreciated. The students underline that one can still have a lot of great experiences in the city, in spite of the regulations. Bilousov, Vinnikainen, Colaneri and Fenton are all CEMS students. Bilousov, explains that for “Cemsies” it is mandatory to take a semester abroad. Vinnikainen was originally set to travel to India, but it got cancelled due to the coronavirus situation, and she eventually ended up in Bergen instead. They both emphasize on how Bergen feels like a safer place to be amid the pandemic compared to many other places at the moment, while Fenton says he was “desperate for an in-person experience”. Generally, this seems to be a common feeling among the exchange stu
EU recovery plan has helped boost consumer, industry confidence
euractiv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from euractiv.com Daily Mail and Mail on Sunday newspapers.
Oxurion NV Business and Financial Update
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year
THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020
The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.
At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021. The Company is in advanced discussions with potential investors in order to increase its cash position.
First patients dosed in Phase 2 study (‘KALAHARI’) evaluating multiple injections of THR-149, a potent plasma kallikrein inhibitor, for the treatment of DME. Part A data expected by mid-year
THR-687, a pan-RGD integrin antagonist, Phase 2 DME study planned to start by mid-year, following positive Phase 1 data released in 2020
The Company has strengthened the management team with the appointments of Tom Graney, CFA, based in Boston as CFO, Grace Chang M.D., PhD, based in LA as CMO, and Professor Alan Stitt, PhD as CSO.
At the end of December 2020, Oxurion had cash, cash equivalents & investments of €24.8 million, allowing the Company to execute on its business plans through the end of Q3 2021. The Company is in advanced discussions with potential investors in order to increase its cash position.